文献速递炎症性肠病肝病

炎症性肠病患者代谢相关脂肪性肝病及肝纤维化风险增加且独立于经典代谢危险因素

Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-03

这项横断面病例对照研究纳入831例炎症性肠病患者和1718例年龄、性别、2型糖尿病状态及体重指数匹配的普通人群对照,发现炎症性肠病患者代谢相关脂肪性肝病患病率为42.00%、进展性肝纤维化(瞬时弹性成像≥9.7 kPa)为9.50%,均高于普通人群的32.77%和2.31%(P < .001);炎症性肠病是代谢相关脂肪性肝病(调整比值比1.99)和进展性肝纤维化(调整比值比5.55)的独立预测因素。

要点

  • 炎症性肠病患者代谢相关脂肪性肝病患病率为42.00%,普通人群为32.77%(P < .001)。
  • 炎症性肠病患者进展性肝纤维化(瞬时弹性成像≥9.7 kPa)为9.50%,普通人群为2.31%。
  • 炎症性肠病是代谢相关脂肪性肝病(调整比值比1.99)和进展性肝纤维化(调整比值比5.55)的独立预测因素。

核心结论

  • 代谢相关脂肪性肝病和肝纤维化在炎症性肠病患者中尤为常见,且不受经典代谢危险因素的影响。

研究设计与样本

  • 横断面病例对照研究,连续纳入2所不同大学医院治疗的831例炎症性肠病患者。
  • 对照为随机选自普通人群、按年龄、性别、2型糖尿病状态和体重指数1:2匹配的1718例受试者。
  • 代谢相关脂肪性肝病通过受控衰减参数确认;疑似代谢相关脂肪性肝病伴显著肝纤维化时采集肝活检。
  • 另设年龄和纤维化分期配对的非炎症性肠病活检证实代谢相关脂肪性肝病患者作为二次对照组。

主要发现

  • 炎症性肠病患者代谢相关脂肪性肝病患病率为42.00%,普通人群为32.77%(P < .001)。
  • 炎症性肠病患者进展性肝纤维化(瞬时弹性成像≥9.7 kPa)患病率为9.50%,普通人群为2.31%(P < .001)。
  • 炎症性肠病是代谢相关脂肪性肝病的独立预测因素(调整比值比1.99;P < .001)。
  • 炎症性肠病是进展性肝纤维化的独立危险因素(调整比值比5.55;P < .001)。
  • 40例炎症性肠病患者接受肝活检,全部确认代谢相关脂肪性肝病,25/40例(62.5%)确认任何程度的纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients. METHODS: Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age- and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group. RESULTS: Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography ≥9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD. CONCLUSIONS: MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2022. PMID: 35124272. doi:10.1016/j.cgh.2022.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。